[HTML][HTML] A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells
C Coffinier, SE Hudon, R Lee, EA Farber… - Journal of Biological …, 2008 - ASBMB
HIV protease inhibitors (HIV-PIs) are key components of highly active antiretroviral therapy,
but they have been associated with adverse side effects, including partial lipodystrophy and
metabolic syndrome. We recently demonstrated that a commonly used HIV-PI, lopinavir,
inhibits ZMPSTE24, thereby blocking lamin A biogenesis and leading to an accumulation of
prelamin A. ZMPSTE24 deficiency in humans causes an accumulation of prelamin A and
leads to lipodystrophy and other disease phenotypes. Thus, an accumulation of prelamin A …
but they have been associated with adverse side effects, including partial lipodystrophy and
metabolic syndrome. We recently demonstrated that a commonly used HIV-PI, lopinavir,
inhibits ZMPSTE24, thereby blocking lamin A biogenesis and leading to an accumulation of
prelamin A. ZMPSTE24 deficiency in humans causes an accumulation of prelamin A and
leads to lipodystrophy and other disease phenotypes. Thus, an accumulation of prelamin A …